MaxCyte (MXCT) Stock Price, News & Analysis

Company Overview

MaxCyte, Inc. is a life sciences company that develops cell-engineering technologies for use in cell therapy, gene editing, biomanufacturing and drug discovery. Its platform is designed to introduce molecules, such as nucleic acids and proteins, into cells while supporting the development and production of advanced therapies.

The company’s primary offering is the ExPERT platform, which combines electroporation instruments, disposable processing assemblies and related software. MaxCyte also provides research, development and commercialization support to biotechnology and pharmaceutical companies using its technology. Its systems are used with a range of cell types and are intended to support applications from early-stage research through clinical and commercial manufacturing.

MaxCyte serves biotechnology companies, pharmaceutical manufacturers and academic or research institutions worldwide. The company is headquartered in Rockville, Maryland, and has built its business through direct sales and strategic partnerships with companies developing cell and gene therapies. Maher Masoud serves as president and chief executive officer.

Key Stats

• Today's Range: $1.07 to $1.11
• 50-Day Range: $1.01 to $1.39
• 52-Week Range: $0.64 to $1.87
• Volume: 228,091 shs
• Average Volume: 341,384 shs
• Market Capitalization: $110.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Hold

MaxCyte Stock Analysis - MarketRank™

MaxCyte scored higher than 55% of companies evaluated by MarketBeat, and ranked 425th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

MaxCyte has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

MaxCyte has a consensus price target of $5.00, representing about 367.3% upside from its current price of $1.07.

Amount of Analyst Coverage

MaxCyte has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MaxCyte are expected to grow in the coming year, from ($0.25) to ($0.19) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MaxCyte is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MaxCyte is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MaxCyte has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.18% of the float of MaxCyte has been sold short.

Short Interest Ratio / Days to Cover

MaxCyte has a short interest ratio ("days to cover") of 2.81, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MaxCyte has recently decreased by 10.09%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MaxCyte does not currently pay a dividend.

Dividend Growth

MaxCyte does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for MaxCyte this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MaxCyte insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.10% of the stock of MaxCyte is held by insiders.

Percentage Held by Institutions

68.81% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:MXCT
• CIK: 1287098
• Web: maxcyte.com
• Phone: (301) 517-5556
• Fax: 301-944-1703
• Employees: 91
• Year Founded: 1998

Price Target and Rating

• Average Price Target for MaxCyte: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: +367.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$44.63 million
• Net Margins: -114.77%
• Pretax Margin: -114.77%
• Return on Equity: -18.92%
• Return on Assets: -16.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.26
• Quick Ratio: 11.47

Sales & Book Value

• Annual Sales: $33.03 million
• Price / Sales: 3.34
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.61 per share
• Price / Book: 0.66

Miscellaneous

• Outstanding Shares: 103,210,000
• Free Float: 98,975,000
• Market Cap: $110.43 million
• Optionable: Optionable
• Beta: 1.49